Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More generic competition for Sanofi's Eloxatin in Europe as Strides gets UK nod

This article was originally published in Scrip

Executive Summary

Even as Sanofi-Aventis continues to rake in US sales of its colon cancer drug Eloxatin (oxaliplatin injection) through a court order keeping generic versions off the market there, more firms are set to launch into Europe.

You may also be interested in...



Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

India-China Tango: Can Gland Sustain Listing Luster?

Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?

A Peek At How Janssen’s Supply Chain Withstood COVID-19 Disruptions

A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.

Topics

Related Companies

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel